Walleye Trading’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.8M Sell
54,100
-75,000
-58% -$16.6M 0.02% 714
2025
Q4
$29.5M Sell
129,100
-74,700
-37% -$17M 0.04% 454
2025
Q3
$47.2M Buy
203,800
+20,300
+11% +$4.13M 0.07% 275
2025
Q2
$34.1M Sell
183,500
-26,600
-13% -$4.94M 0.06% 333
2025
Q1
$44M Buy
210,100
+89,200
+74% +$17.3M 0.1% 196
2024
Q4
$21.5M Sell
120,900
-1,100
-0.9% -$202K 0.05% 456
2024
Q3
$24.1M Buy
122,000
+9,500
+8% +$1.77M 0.05% 386
2024
Q2
$19.3M Sell
112,500
-21,100
-16% -$3.5M 0.05% 423
2024
Q1
$24.3M Sell
133,600
-98,700
-42% -$17M 0.05% 347
2023
Q4
$36M Buy
232,300
+21,500
+10% +$3.13M 0.08% 243
2023
Q3
$31.4M Buy
210,800
+51,900
+33% +$7.62M 0.08% 224
2023
Q2
$21.4M Buy
158,900
+12,500
+9% +$1.83M 0.06% 285
2023
Q1
$23.3M Sell
146,400
-63,600
-30% -$9.72M 0.05% 332
2022
Q4
$33.9M Sell
210,000
-14,000
-6% -$2.15M 0.1% 218
2022
Q3
$30.1M Buy
224,000
+13,500
+6% +$1.94M 0.09% 213
2022
Q2
$32.2M Sell
210,500
-293,700
-58% -$44.9M 0.1% 185
2022
Q1
$81.7M Buy
504,200
+349,300
+226% +$50.7M 0.26% 50
2021
Q4
$21M Sell
154,900
-25,500
-14% -$3.01M 0.07% 304
2021
Q3
$19.5M Buy
180,400
+139,500
+341% +$15.9M 0.07% 293
2021
Q2
$4.61M Sell
40,900
-53,500
-57% -$6.03M 0.02% 848
2021
Q1
$10.2M Sell
94,400
-96,276
-50% -$10.3M 0.05% 314
2020
Q4
$20.4M Sell
190,676
-323,300
-63% -$31.1M 0.09% 173
2020
Q3
$45M Buy
513,976
+114,206
+29% +$10.8M 0.24% 41
2020
Q2
$39.2M Buy
399,770
+217,470
+119% +$19.1M 0.25% 42
2020
Q1
$13.9M Sell
182,300
-97,300
-35% -$8.29M 0.11% 115
2019
Q4
$24.8M Sell
279,600
-51,500
-16% -$4.28M 0.17% 94
2019
Q3
$25.1M Buy
331,100
+168,900
+104% +$11.6M 0.21% 52
2019
Q2
$11.8M Buy
162,200
+19,000
+13% +$1.49M 0.1% 165
2019
Q1
$11.5M Sell
143,200
-79,700
-36% -$6.52M 0.09% 209
2018
Q4
$20.5M Sell
222,900
-56,500
-20% -$4.97M 0.15% 98
2018
Q3
$26.4M Buy
279,400
+159,600
+133% +$15.1M 0.14% 97
2018
Q2
$11.1M Buy
119,800
+100,600
+524% +$9.82M 0.06% 265
2018
Q1
$1.82M Sell
19,200
-65,400
-77% -$7.18M 0.01% 1292
2017
Q4
$8.18K Sell
84,600
-145,600
-63% -$13.7M 0.04% 420
2017
Q3
$20.5K Sell
230,200
-528,900
-70% -$40.3M 0.1% 132
2017
Q2
$55K Buy
759,100
+152,300
+25% +$10.2M 0.34% 22
2017
Q1
$39.5K Buy
606,800
+125,800
+26% +$7.91M 0.28% 26
2016
Q4
$30.1M Buy
481,000
+113,100
+31% +$6.9M 0.21% 39
2016
Q3
$23.2M Buy
367,900
+170,100
+86% +$11M 0.15% 58
2016
Q2
$12.2M Sell
197,800
-40,700
-17% -$2.48M 0.08% 157
2016
Q1
$13.6M Buy
238,500
+169,900
+248% +$9.47M 0.12% 138
2015
Q4
$4.07M Buy
68,600
+12,700
+23% +$731K 0.04% 441
2015
Q3
$3.04M Sell
55,900
-380,006
-87% -$24.7M 0.03% 469
2015
Q2
$29.3M Buy
435,906
+258,606
+146% +$16.9M 0.29% 42
2015
Q1
$10.4M Sell
177,300
-143,500
-45% -$8.67M 0.1% 141
2014
Q4
$21M Buy
320,800
+291,800
+1,006% +$18.4M 0.19% 61
2014
Q3
$1.68M Sell
29,000
-9,100
-24% -$505K 0.02% 533
2014
Q2
$2.15K Sell
38,100
-40,200
-51% -$2.11M 0.03% 384
2014
Q1
$4.03K Sell
78,300
-15,300
-16% -$773K 0.06% 199
2013
Q4
$4.94M Buy
93,600
+45,700
+95% +$2.25M 0.05% 288
2013
Q3
$2.14M Buy
47,900
+3,000
+7% +$133K 0.02% 527
2013
Q2
$1.86M Buy
+44,900
New +$1.96M 0.02% 613

Other funds holding ABBV

Walleye Trading's ABBV Position: Q1 2026 in Review

Walleye Trading reduced its AbbVie (ABBV) stake by 48% in Q1 2026, selling an estimated $8.81M and leaving 42,217 shares worth $9.18M. The position accounts for 0.02% of the portfolio, ranked #833.

Walleye Trading first reported a position in ABBV in Q2 2013 and has held it in 28 quarters since. The position peaked at $18.7M in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Walleye Trading held 42,217 shares of AbbVie worth $9.18M as of Q1 2026.
  • Walleye Trading sold 39,716 AbbVie shares in Q1 2026, an estimated $8.81M.
  • AbbVie made up 0.02% of Walleye Trading's portfolio in Q1 2026, its #833 holding.
  • Walleye Trading first reported a position in AbbVie in Q2 2013 and has held it in 28 quarters since.
  • Walleye Trading's AbbVie position peaked at $18.7M in Q4 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.